So What’s Next For Hanmi?
This article was originally published in PharmAsia News
Hanmi's surprising success in R&D this year has left people wondering what strategy the leading South Korean pharma firm may take next to transform into a big global player like Takeda. With an expected massive inflow of cash from a series of big licensing out deals with multinationals, it may be poised to change its R&D strategy and even engage in some M&A.
You may also be interested in...
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.